Although several strategies for inhibiting FAK protein expression, such as interfering with the ATP-binding pocket of FAK and inhibiting the phosphorylation of FAK, have been developed [51], combinational therapy with other therapeutics is still the dominant method because FAK inhibitors are insufficient to fully treat cancer [52,53]. The gene discussed is PTK2; the disease is cancer.